Update SRA to SRIA 28 March 2017 Linda van Gaalen Update SRA - - PowerPoint PPT Presentation

Update SRA to SRIA

28 March 2017 Linda van Gaalen

Update SRA

‒ First SRA approved 2013 ‒ New CSA (EXEDRA): Add Innovation to SRA => SRIA ‒ Other WPs CSA will provide input ‒ Alignment necessary: ‒ with other SR(I)A’s (eg. SRIA-IMI) ‒ stakeholders / industry ‒ national action plans ‒ WHO Global Action Plan

Important choices! ‒ SRIA specific for JPIAMR

• r
• General SRIA (added value JPI indicated)

‒ Update or amendment?

Procedure

1. Desk study existing SRIA’s 2. Questionnaires: critical areas to reappraise (MB & SAB). 3. Workshops to prioritise research areas: roadmaps by SRIA pillar (WP 2 & EXEDRA WS) 4. Engagement with industry and stakeholders (WP3 & WP 4) 5. Draft 1 SRIA with SAB 6. Feedback: MB, Stakeholders & Industry 7. Draft 2 SRIA with SAB 8. Approval MB

What do we need

‒ MB approval on procedure ‒ Editorial board (?) ‒ Scope and strategic plan (CSA) ‒ List of stakeholders and industry to contact ‒ List of critical areas to reappraise from questionnaires ‒ List of prioritisation research areas from roadmaps ‒ Input from expert meeting ‒ Approval MB on SRIA ‒ Broad attention for SRIA through communication network

Planning and relation to EXEDRA activities M1-12

Relation What WP Task leader -

• rganiser

Due date (Month)

Base of the update SRIA is scope and strategic plan Scope - strategic plan JPIAMR EXEDRA 2 ISCII - Spain 3 Opinion of SAB and MB Questionnaire to MB - SAB on current SRA 5.1 ZON - Netherlands 5 SAB meeting ZON - Netherlands 6 Alignment with other SRA's (WHO and others) Desk study & consultation partner countries 5.1 ZON - Netherlands 7 Work Shop Environmental SRC - Sweden 9 Work Shop Virtual Institute DLR - Germany 9 Work Shop Interventions ISCII - Spain 10 MB Meeting SRC - Sweden 10 CSA EXEDRA meeting SRC - Sweden 10 SAB meeting ZON - Netherlands 12 Editorial board for Update SRA Establish editorial board SAB - MB - SH? 5.1 ZON - Netherlands 12 Engagement stakeholders /

• ther countries

for Update SRA Mapping and analysis international collaboration 3 DLR - Germany 12 Engagement stakeholders /

• ther countries

for Update SRA Strengthen dialogue with industry 4.2 ANR - France 12

Planning and relation to EXEDRA activities M13-24

Relation What WP Task leader -

• rganiser

Due date (month)

Engagement stakeholders / other countries alignment strategy with national policy makers and international SH 4.1 SRC - Sweden 15 Draft 1 SAB development Draft 1 jan-march 2018 5.1 ZON - Netherlands 16 Stakeholder and industry feedback Expert meeting on Draft 1 April-May 2018 5.1 ZON - Netherlands 17 Draft 2 SAB development Draft 2 May - June 2018 5.1 ZON - Netherlands 18 Feedback Participants

• n draft 2 SRIA

Distribute draft 2 SRIA 5.1 ZON - Netherlands 18 Final SRIA SAB development Final SRIA Sept -Oct 2018 5.1 ZON - Netherlands 19 Final approval of member countries SRIA Distribute final SRIA October 2018 5.1 ZON - Netherlands 23 Update SRIA publication of the SRIA 5.1 ZON - Netherlands 24 Use communication channels Promotion SRIA 6.2 SRC - Sweden 12-48

Questions to take into account

• 1. Which innovation aspects will be an addition to the present

SRA?

• 2. How does the SRA relate and align with industry and initiatives

such as IMI, etc?

• 3. How can translational research be stimulated?
• 4. How can key networks of academic and industrial excellence

be developed and involved?

• 5. What are priorities in the current pillars?
• 6. What are key areas for implementation of the SRA?
• 7. How can we measure or define “value added” to the SRIA?
• 8. What are other key areas or instruments we should think of?

Current strategic research priorities SRA

• A. Therapeutics
• B. Diagnostics
• C. Surveillance
• D. Transmission
• E. Environment
• F. Interventions

Objectives WHO Global Action Plan AMR

• 1. Improve awareness and understanding of antimicrobial

resistance through effective communication, education and training

• 2. Strengthen the knowledge and evidence base through

surveillance and research

• 3. Reduce the incidence of infection through effective sanitation,

hygiene and infection prevention measures

• 4. Optimize the use of antimicrobial medicines in human and animal

health

• 5. Develop the economic case for sustainable investment that takes

account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions

Questions

1. General or specific SRIA? 2. Update or amendment? 3. Approval procedure 4. Editorial board (M12)? Yes / No? If yes; any suggestions?

• MB, SAB, Stakeholders, Others

@: abr@zonmw.nl